Teva Pharmaceutical Industries (TEVA) Receivables (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Receivables came in at $3.5 billion in Q2 2026, down 1.99% YoY from $3.6 billion in Q2 2025, and up 2.95% on a QoQ basis from $3.4 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Receivables (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Receivables data on file, last reported at $3.5 billion in Q2 2026.
- Quarterly Receivables fell 1.99% year-over-year to $3.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.5 billion (down 1.99% YoY) and the FY2025 annual result came in at $3.7 billion, up 21.25% from the prior year.
- Receivables advanced to $3.5 billion in Q2 2026, from $3.4 billion in the prior quarter.
- In the past five years, Receivables ranged from a high of $4.5 billion in Q2 2022 to a low of $3.1 billion in Q4 2024.
- A 5-year average of $3.6 billion and a median of $3.5 billion in 2023 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables decreased 20.85% — and 2025, when it rose 21.25%.
- Tracing TEVA's Receivables over 5 years: stood at $3.7 billion in 2022, then retreated by 7.79% to $3.4 billion in 2023, then slipped by 10.24% to $3.1 billion in 2024, then grew by 21.25% to $3.7 billion in 2025, then slipped by 5.82% to $3.5 billion in 2026.
- The last three Receivables figures came in at $3.5 billion (Q2 2026), $3.4 billion (Q1 2026), and $3.7 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.08 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 456.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.49 Bn |
| Mar 31, 2026 | 3.39 Bn |
| Dec 31, 2025 | 3.71 Bn |
| Sep 30, 2025 | 3.81 Bn |
| Jun 30, 2025 | 3.56 Bn |
| Mar 31, 2025 | 3.38 Bn |
| Dec 31, 2024 | 3.06 Bn |
| Sep 30, 2024 | 3.46 Bn |
| Jun 30, 2024 | 3.77 Bn |
| Mar 31, 2024 | 3.46 Bn |
| Dec 31, 2023 | 3.41 Bn |
| Sep 30, 2023 | 3.39 Bn |
| Jun 30, 2023 | 3.54 Bn |
| Mar 31, 2023 | 3.44 Bn |
| Dec 31, 2022 | 3.70 Bn |
| Sep 30, 2022 | 3.73 Bn |
| Jun 30, 2022 | 4.47 Bn |
| Mar 31, 2022 | 4.25 Bn |
| Dec 31, 2021 | 4.53 Bn |
| Sep 30, 2021 | 4.05 Bn |